Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.

3013 Background: IPI-549 is a potential first-in-class, oral, selective PI3K-γ inhibitor that in preclinical studies reprograms macrophages from an immune-suppressive to an immune-activating phenotype and can overcome resistance to checkpoint inhibitors. Methods: Ph 1/1b study IPI-549-01 (NCT02637531) is evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunomodulatory activity of IPI-549 to determine its...